晚期卵巢癌-话题@MedSci

#晚期卵巢癌#

59篇内容 | 1462人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1394571, encodeId=08cc13945e1d4, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用, objectType=article, longId=197251, objectId=93ea19e25141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93ea19e25141, replyNumber=0, likeNumber=37, createdTime=2020-07-10, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93ea19e25141, moduleTitle=Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93ea19e25141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394570, encodeId=687013945e005, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯, objectType=article, longId=193965, objectId=a65b19396562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a65b19396562, replyNumber=0, likeNumber=59, createdTime=2020-05-13, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a65b19396562, moduleTitle=LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a65b19396562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394569, encodeId=4de9139456993, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, objectType=article, longId=193374, objectId=b40b1933e4d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40b1933e4d3, replyNumber=0, likeNumber=36, createdTime=2020-05-03, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40b1933e4d3, moduleTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b40b1933e4d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394568, encodeId=a57e13945683c, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, objectType=article, longId=188795, objectId=27b9188e9585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27b9188e9585, replyNumber=0, likeNumber=39, createdTime=2020-02-27, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27b9188e9585, moduleTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27b9188e9585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394567, encodeId=1931139456eca, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=NEJM：奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌, objectType=article, longId=184966, objectId=1d4b184966ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d4b184966ae, replyNumber=0, likeNumber=30, createdTime=2019-12-21, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d4b184966ae, moduleTitle=NEJM：奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d4b184966ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394566, encodeId=b28313945669c, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=NEJM：Niraparib一线治疗晚期卵巢癌, objectType=article, longId=184964, objectId=1d621849647a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d621849647a, replyNumber=0, likeNumber=36, createdTime=2019-12-21, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d621849647a, moduleTitle=NEJM：Niraparib一线治疗晚期卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d621849647a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394565, encodeId=67af139456588, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗, objectType=article, longId=184088, objectId=1ff918408873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff918408873, replyNumber=0, likeNumber=33, createdTime=2019-12-05, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff918408873, moduleTitle=NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ff918408873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394564, encodeId=1f361394564ba, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌, objectType=article, longId=180570, objectId=29001805e099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29001805e099, replyNumber=0, likeNumber=42, createdTime=2019-10-07, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29001805e099, moduleTitle=2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29001805e099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394563, encodeId=659313945630c, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, objectType=article, longId=180550, objectId=a9941805506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9941805506a, replyNumber=0, likeNumber=33, createdTime=2019-10-07, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9941805506a, moduleTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9941805506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394562, encodeId=dc46139456231, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=Clinica Chimica Acta：晚期卵巢癌细胞外小泡表面的金属蛋白酶与腹水体积和腹膜肿瘤指数的关系, objectType=article, longId=179431, objectId=12961e943196, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12961e943196, replyNumber=0, likeNumber=30, createdTime=2019-09-15, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12961e943196, moduleTitle=Clinica Chimica Acta：晚期卵巢癌细胞外小泡表面的金属蛋白酶与腹水体积和腹膜肿瘤指数的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12961e943196)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394561, encodeId=4b4d13945619a, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, objectType=article, longId=177714, objectId=d4e41e7714e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4e41e7714e1, replyNumber=0, likeNumber=46, createdTime=2019-08-17, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4e41e7714e1, moduleTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4e41e7714e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394560, encodeId=5f12139456097, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着, objectType=article, longId=167750, objectId=63b216e750f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63b216e750f8, replyNumber=0, likeNumber=40, createdTime=2019-06-07, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63b216e750f8, moduleTitle=2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63b216e750f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394559, encodeId=f50b139455966, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=Lancet Oncol：Trebananib联合紫杉醇和卡铂作为一线疗法用于晚期卵巢癌患者的疗效和安全性, objectType=article, longId=166883, objectId=967c166883ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=967c166883ab, replyNumber=0, likeNumber=32, createdTime=2019-05-28, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=967c166883ab, moduleTitle=Lancet Oncol：Trebananib联合紫杉醇和卡铂作为一线疗法用于晚期卵巢癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=967c166883ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394558, encodeId=83121394558cb, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=晚期卵巢癌：Rubraca的III期ARIEL3研究的全新数据, objectType=article, longId=166644, objectId=25351666441e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25351666441e, replyNumber=0, likeNumber=36, createdTime=2019-05-24, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25351666441e, moduleTitle=晚期卵巢癌：Rubraca的III期ARIEL3研究的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25351666441e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394557, encodeId=3ab6139455e10, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=中国专家让“最凶妇癌”变乖晚期卵巢癌或变慢性病, objectType=article, longId=165600, objectId=0a1a1656003f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a1a1656003f, replyNumber=0, likeNumber=36, createdTime=2019-05-09, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a1a1656003f, moduleTitle=中国专家让“最凶妇癌”变乖晚期卵巢癌或变慢性病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a1a1656003f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394556, encodeId=8e431394556c8, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=【NEJM】SOLO 1研究：奥拉帕利进军晚期卵巢癌一线维持治疗, objectType=article, longId=152193, objectId=2532152193a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2532152193a4, replyNumber=0, likeNumber=38, createdTime=2018-10-31, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2532152193a4, moduleTitle=【NEJM】SOLO 1研究：奥拉帕利进军晚期卵巢癌一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2532152193a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394555, encodeId=5c37139455575, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=晚期卵巢癌续命新药欧洲上市，有效延长患者生命！, objectType=article, longId=133439, objectId=a7b613343933, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7b613343933, replyNumber=0, likeNumber=33, createdTime=2018-03-27, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7b613343933, moduleTitle=晚期卵巢癌续命新药欧洲上市，有效延长患者生命！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7b613343933)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394554, encodeId=c639139455482, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=EUR J Cancer：对于接受新型辅助治疗后进行间隔减瘤手术的晚期卵巢癌患者使用贝伐单抗的安全性和有效性, objectType=article, longId=125221, objectId=7f3b1252214c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f3b1252214c, replyNumber=0, likeNumber=44, createdTime=2018-01-02, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f3b1252214c, moduleTitle=EUR J Cancer：对于接受新型辅助治疗后进行间隔减瘤手术的晚期卵巢癌患者使用贝伐单抗的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f3b1252214c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394553, encodeId=1055139455309, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=Oncotarget：系统性淋巴结切除术在晚期卵巢癌中发挥的作用：根治性手术时代的再评估, objectType=article, longId=101801, objectId=e06410180151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e06410180151, replyNumber=0, likeNumber=0, createdTime=2017-06-15, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e06410180151, moduleTitle=Oncotarget：系统性淋巴结切除术在晚期卵巢癌中发挥的作用：根治性手术时代的再评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e06410180151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394552, encodeId=5e3713945525d, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=晚期卵巢癌患者福音！二代测序助力FDA加速批准卵巢癌新药, objectType=article, longId=85280, objectId=040d85280b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=040d85280b1, replyNumber=0, likeNumber=38, createdTime=2016-12-25, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=040d85280b1, moduleTitle=晚期卵巢癌患者福音！二代测序助力FDA加速批准卵巢癌新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=040d85280b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期卵巢癌

2020-05-29

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用

2020-07-10

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯

2020-05-13

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗

2020-05-03

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗

2020-02-27

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

NEJM：奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌

2019-12-21

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

NEJM：Niraparib一线治疗晚期卵巢癌

2019-12-21

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗

2019-12-05

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌

2019-10-07

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期

2019-10-07

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

Clinica Chimica Acta：晚期卵巢癌细胞外小泡表面的金属蛋白酶与腹水体积和腹膜肿瘤指数的关系

2019-09-15

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功

2019-08-17

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着

2019-06-07

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

Lancet Oncol：Trebananib联合紫杉醇和卡铂作为一线疗法用于晚期卵巢癌患者的疗效和安全性

2019-05-28

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

晚期卵巢癌：Rubraca的III期ARIEL3研究的全新数据

2019-05-24

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

中国专家让“最凶妇癌”变乖晚期卵巢癌或变慢性病

2019-05-09

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

【NEJM】SOLO 1研究：奥拉帕利进军晚期卵巢癌一线维持治疗

2018-10-31

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

晚期卵巢癌续命新药欧洲上市，有效延长患者生命！

2018-03-27

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

EUR J Cancer：对于接受新型辅助治疗后进行间隔减瘤手术的晚期卵巢癌患者使用贝伐单抗的安全性和有效性

2018-01-02

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

Oncotarget：系统性淋巴结切除术在晚期卵巢癌中发挥的作用：根治性手术时代的再评估

2017-06-15

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

晚期卵巢癌患者福音！二代测序助力FDA加速批准卵巢癌新药

2016-12-25

科室
- - 订阅+
  - 更多科室
工具
服务